Hunter Syndrome Market is shooting up at a CAGR of 7.49% during the forecast period 2020-2030, states DelveInsight

LAS VEGAS, Jan. 19, 2021 /PRNewswire/ -- DelveInsight's "Hunter Syndrome Market Report" report provides a thorough comprehension of the Hunter Syndrome, historical and forecasted epidemiology and the Hunter Syndrome market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Hunter Syndrome market report also proffers an analysis of recent Hunter Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs. 

Some of the key features of the Hunter Syndrome Market Research Report: 

• The FDA has approved only one drug, Elaprase (idursulfase), and is used for treating Hunter Syndrome patients. The drug was essentially developed by the Shire.
• Hunter Syndrome pipeline is robust and possesses several potential drugs in late and mid-stage developments to be launched soon. JR-141 is presently in the phase III stage of development followed by TAK-609 and Hunterase in phase II clinical development and DNL310, RGX-121, SB-913 and TAK-531 in phases I/II and I clinical development. 
• The market is anticipated to witness a substantial positive shift in the Hunter Syndrome market size owing to the positive results of the various products during the developmental stages by the prominent players such as JCR Pharmaceuticals, GC Pharma, Takeda, Denali Therapeutics, Regenxbio and Sangamo Therapeutics, and many others. 
• The one-time use of gene replacement therapies, once approved, by Regenxbio and Sangamo Therapeutics will drive the Hunter Syndrome market revenue to reach great heights, resulting in a new class of therapy for Mucopolysaccharidosis type II (MPS II) patients. 
• The current Hunter Syndrome therapeutic landscape in the United States is driven by current treatment practices and expected launch of emerging therapies.

For further information on Market Impact by Therapies, visit:  Hunter Syndrome Market Analysis

Hunter Syndrome, aka Mucopolysaccharidosis type II (MPS II), is a condition that affects many various parts of the body and mainly affects males. It is a progressive disorder, but the rate of progression varies among affected individuals. It is a rare, X-linked disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase that plays a chief role in the catabolism of glycosaminoglycans (GAG). The total diagnosed Hunter Syndrome prevalent population in the 7MM (the US, EU5 [the UK, Italy, Germany, Spain, and France] and Japan] was 1,166 in 2020. 

The Hunter Syndrome Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

• Total Diagnosed Prevalent Population of Hunter Syndrome
• Severity-based Diagnosed Prevalent Population of Hunter Syndrome 

Request for a free sample report for more insights @ Hunter Syndrome Treatment Market Trends Analysis 

Hunter Syndrome Treatment Market Analysis 

Hunter Syndrome treatments are aimed at providing replacement of I2S in the disease that have been reported, including fibroblast transplantation, serum or plasma infusion, white blood cell infusions, and human amnion membrane implantation. These treatments have been tested in single patients or in small series of patients, and no evidence of clinical benefit has been reported. Other methods include hematopoietic stem cell transplantation (HSCT) and enzyme-replacement therapy (ERT) with recombinant human I2S. Only recombinant human I2S has been tested in randomized clinical trials.

There is only one FDA approved drug used for treating patients with Hunter Syndrome, namely, Elaprase (idursulfase), which was essentially developed by the Shire. However, In January 2019, Takeda acquired the Shire, thereby becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. 

Hunter Syndrome market dynamics are anticipated to change in the future due to the enhancement in the research and development activities so that market will involve efficient treatment options. The launch of emerging therapies is awaited during the forecast period of 2021-2030.

Hunter Syndrome Emerging Therapies 

• JR-141
• TAK-609/SHP609/HGT-2310
• GC1111 (Hunterase)
• DNL310
• RGX-121
• SB-913

And several others. 

Leading Players operating in the Hunter Syndrome Treatment Market are:

• JCR Pharmaceuticals
• Takeda
• Green Cross Corporation/GC Pharma
• Denali Therapeutics
• Regenxbio
• Sangamo Therapeutics

And several others. 

For more information about this report visit @ Hunter Syndrome Market Infographic

Final Thoughts on Hunter Syndrome Market Analysis 

Hunter Syndrome Market Drivers are attributable to 

• Robust pipeline activity with the emergence of enzyme replacement therapies as well as gene therapies- Once approved, the one-time use of gene replacement therapies by Regenxbio and Sangamo Therapeutics will drive the Hunter Syndrome market revenue to reach great heights, resulting in a new class of therapy for MPS II patients. 
• Increasing awareness of Hunter Syndrome- Several organizations are actively working to provide information and awareness of such rare and devastating disorders. Thriving R&D to understand the diversity of the disease might improve the MPS II diagnosis, thereby resulting in a lucrative Hunter Syndrome market opportunity. The current treatment options are very few for treating patients with MPS II, which opens a platform of new therapies to boost the Hunter Syndrome market. 
• Reimbursement of Elaprase. 

Nevertheless, there are a few impediments to Hunter Syndrome market growth:- 

• Drawbacks of Elaprase - There is only one approved therapy till date to treat MPS II, i.e. Elaprase, which also has a significant downside that cannot cross the blood-brain barrier. Also, there is no definitive cure available to date to cure MPS II completely.
• High Cost of Therapy - Gene therapies are quite costly, far more expensive than the enzyme replacement therapies, which pose a major threat to the Hunter Syndrome market. 
• Adverse Events of Current Treatment Options - The current available approved therapy poses a cost-burden on the MPS II patients, resulting in decreased quality of life. Also, adverse events of current treatment options such as allergic reactions, skin rashes etc. due to use of Elaprase also pose a threat to the MPS II market. The majority of patients suffer due to severe phenotype of the disease for which efficient treatment options are lacking. Delayed or late diagnosis of MPS II depicts the non-availability of robust diagnostic methodologies.

Scope of the Hunter Syndrome Report

• Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
• Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
• Hunter Syndrome Markets Segmentation: By Geographies and By Hunter Syndrome Therapies (Historical and Forecasted, Current and Upcoming)
• Leading Companies Covered: JCR Pharmaceuticals, Takeda, Green Cross Corporation/GC Pharma, Denali Therapeutics, Regenxbio, Sangamo Therapeutics, among others.
• Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis.
• Case Studies
• KOL's Views
• Analyst's View

Request for a Webex demo of the report @ Hunter Syndrome Treatment Market Share Analysis 

Table of Contents 

Related Reports              

• Hunter Syndrome Epidemiology Forecast Analysis 

DelveInsight's Hunter Syndrome - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hunter Syndrome. 

• Hunter Syndrome Pipeline Analysis 

Hunter Syndrome Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hunter Syndrome market.

• Fragile X Syndrome Market Analysis 

DelveInsight' s Fragile X Syndrome Market Insights, Epidemiology & Market Forecast 2030 report provides an overview of the disease & understanding of historical and forecasted epidemiology. 

• Cytokine Release Syndrome Market Analysis 

DelveInsight's Cytokine Release Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. 

• Sjogren's Syndrome Market Analysis 

DelveInsight's 'Sjogren's Syndrome (SS) - Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology.

• Polycystic Ovarian Syndrome Market Analysis 

DelveInsight' s Polycystic Ovarian Syndrome Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology. 

• Leigh Syndrome Market Analysis 

DelveInsight' s Leigh Syndrome Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology. 

• Irritable Bowel Syndrome Market Analysis 

DelveInsight' s Irritable Bowel Syndrome Market Insights, Epidemiology and Market Forecast - 2030 report offers a detailed overview and understanding of historical and forecasted epidemiology. 

• Pleural Effusion Market Analysis 

DelveInsight' s Pleural Effusion - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.

• Polycystic Kidney Disease Market Analysis 

DelveInsight' s Polycystic Kidney Disease - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.

DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
[email protected]
+1(919)321-6187 
DelveInsight

SOURCE DelveInsight Business Research, LLP